跳转至内容
Merck
CN
  • DNA methylation prevents CTCF-mediated silencing of the oncogene BCL6 in B cell lymphomas.

DNA methylation prevents CTCF-mediated silencing of the oncogene BCL6 in B cell lymphomas.

The Journal of experimental medicine (2010-08-25)
Anne Y Lai, Mehrnaz Fatemi, Archana Dhasarathy, Christine Malone, Steve E Sobol, Cissy Geigerman, David L Jaye, Deepak Mav, Ruchir Shah, Leping Li, Paul A Wade
摘要

Aberrant DNA methylation commonly occurs in cancer cells where it has been implicated in the epigenetic silencing of tumor suppressor genes. Additional roles for DNA methylation, such as transcriptional activation, have been predicted but have yet to be clearly demonstrated. The BCL6 oncogene is implicated in the pathogenesis of germinal center-derived B cell lymphomas. We demonstrate that the intragenic CpG islands within the first intron of the human BCL6 locus were hypermethylated in lymphoma cells that expressed high amounts of BCL6 messenger RNA (mRNA). Inhibition of DNA methyltransferases decreased BCL6 mRNA abundance, suggesting a role for these methylated CpGs in positively regulating BCL6 transcription. The enhancer-blocking transcription factor CTCF bound to this intronic region in a methylation-sensitive manner. Depletion of CTCF by short hairpin RNA in neoplastic plasma cells that do not express BCL6 resulted in up-regulation of BCL6 transcription. These data indicate that BCL6 expression is maintained during lymphomagenesis in part through DNA methylation that prevents CTCF-mediated silencing.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
抗磷酸组蛋白H2A.X(Ser139)抗体,克隆JBW301, clone JBW301, Upstate®, from mouse
Sigma-Aldrich
依托泊苷, synthetic, 95.0-105.0%, powder
Sigma-Aldrich
GenomePlex®完整全基因组扩增(WGA)试剂盒, Optimized kit with enzyme for amplifying a variety of DNA including FFPE tissue